Shanghai Hile Bio-Technology Co., Ltd. (SHA:603718)
4.000
-0.010 (-0.25%)
Apr 22, 2026, 11:29 AM CST
SHA:603718 Revenue
Shanghai Hile Bio-Technology had revenue of 39.97M CNY in the quarter ending September 30, 2025, a decrease of -40.20%. This brings the company's revenue in the last twelve months to 246.35M, up 11.70% year-over-year. In the year 2024, Shanghai Hile Bio-Technology had annual revenue of 271.04M with 12.59% growth.
Revenue (ttm)
246.35M
Revenue Growth
+11.70%
P/S Ratio
10.61
Revenue / Employee
673.10K
Employees
366
Market Cap
2.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 271.04M | 30.32M | 12.59% |
| Dec 31, 2023 | 240.72M | -59.27M | -19.76% |
| Dec 31, 2022 | 299.99M | -47.30M | -13.62% |
| Dec 31, 2021 | 347.29M | 88.16M | 34.02% |
| Dec 31, 2020 | 259.13M | -18.86M | -6.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Guangdong VTR Bio-Tech | 830.87M |
| Guiyang Xintian Pharmaceutical | 749.72M |
| Jilin Jian Yisheng Pharmaceutical | 640.17M |
| Hubei Goto Biopharm | 626.28M |
| Suzhou Fushilai Pharmaceutical | 439.57M |